T cell receptor mimic antibodies for cancer therapy Journal Article


Authors: Dubrovsky, L.; Dao, T.; Gejman, R. S.; Brea, E. J.; Chang, A. Y.; Oh, C. Y.; Casey, E.; Pankov, D.; Scheinberg, D. A.
Article Title: T cell receptor mimic antibodies for cancer therapy
Abstract: The major hurdle to the creation of cancer-specific monoclonal antibodies (mAb) exhibiting limited cross-reactivity with healthy human cells is the paucity of known tumor-specific or mutated protein epitopes expressed on the cancer cell surface. Mutated and overexpressed oncoproteins are typically cytoplasmic or nuclear. Cells can present peptides from these distinguishing proteins on their cell surface in the context of human leukocyte antigen (HLA). T cell receptor mimic (TCRm) mAb can be discovered that react specifically to these complexes, allowing for selective targeting of cancer cells. The state-of-the-art for TCRm and the challenges and opportunities are discussed. Several such TCRm are moving toward clinical trials now. © 2016 Taylor & Francis Group, LLC.
Keywords: monoclonal antibody; immunotherapy; t cell receptor (tcr); tcr like antibody; tcr mimic antibody
Journal Title: OncoImmunology
Volume: 5
Issue: 1
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2016-01-01
Start Page: e1049803
Language: English
DOI: 10.1080/2162402x.2015.1049803
PROVIDER: scopus
PMCID: PMC4760335
PUBMED: 26942058
DOI/URL:
Notes: Review -- Export Date: 3 February 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Tao Dao
    57 Dao
  2. Dmitry D. Pankov
    18 Pankov
  3. Emily Catherine Casey
    9 Casey
  4. Ron Shlomo Gejman
    8 Gejman
  5. Elliott Joseph Brea
    13 Brea
  6. Aaron   Chang
    10 Chang
  7. Claire   Oh
    4 Oh